Polygenic risks scores for autoimmune related diseases are significantly different and skewed in cancer exceptional responders
Chen, S.; Tan, A. L. M. L.; Perry, C. L.; Churchill, S.; Vella, M. E.; Mao, J. F.; Viswanadham, V. V.; Kobren, S.; Kohane, I. S.
Show abstract
A group of 54 exceptional responders (ERs) to cancer treatment across a variety of cancers and treatments were compared to typical cancer patients using previously defined polygenic risk scores (PRS) for multiple autoimmune-related diseases including type 1 diabetes (T1D), hypothyroidism, psoriasis, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel (IBD) disease. Most of the ERs were not treated with checkpoint inhibitors and included a broad array of tumor types. Significantly elevated PRSs were found between ERs relative to typical cancer patients in T1D, hypothyroidism, and psoriasis. IBD PRS scores were significantly decreased in the ERs.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Blood cytokine analysis suggests that SARS-CoV-2 infection results in a sustained tumour promoting environment in cancer patients 92%
- Transcriptional reprogramming and constitutive PD-L1 expression in melanoma are associated with dedifferentiation and activation of interferon and tumor necrosis factor signaling pathways 92%
- Sex biases in cancer and autoimmune disease incidence are strongly positively correlated with mitochondrial gene expression across human tissues 92%
Similar papers in this journal
- The association between plasma chemokines and breast cancer risk and prognosis: A Mendelian randomization study 92%
- Computing Skin Cutaneous Melanoma Outcome from the HLA-alleles and Clinical Characteristics 91%
- A tissue specific atlas of gene promoter DNA methylation variability and the clinical value of its assessment 90%
Similar papers in this journal
Similar papers in this journal
- Added-value of whole exome and RNA Sequencing in advanced and refractory cancer patients with no molecular-based treatment recommendation based on a 90-gene panel 91%
- Autoimmune diseases and risk of non-Hodgkin lymphoma: A Mendelian randomisation study 91%
- Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in type 2 diabetes mellitus: a population-based study 90%
Similar papers in this journal
- Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events 92%
- Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab 92%
- Conditional activation of immune-related signatures and prognostic significance: a pan-cancer analysis 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.